Global Pontine Glioma Treatment Market, By Grade (Grade I, Grade II, Grade III and Grade IV), Classification (Diffuse Brain Stem Glioma, Focal Brain Stem Glioma and Recurrent Brain Stem Glioma), Diagnosis (Computed Tomography (CT) Scan, Biopsy and MRI), Treatment (Surgery, Radiotherapy and Chemotherapy), Route of Administration (Oral and Parenteral), End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Pontine Glioma Treatment Market
The pontine glioma treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 3.90% in the above-mentioned research forecast period. Improvement in the research and development for the treatment and diagnosis of pontine glioma may increase the pontine glioma treatment market growth.
For instance,
- The radiation therapy is improved by providing the patients with the conformal radiation in which high doses of therapy which are given to the tumour cells directly which does not affect the healthy cells. It creates 3D maps of the brain so doctors are able to detect the tumors easily.
- Targeted therapies are also used for the treatment of tumours. This treatment directly blocks the growth of the cells.
- Many other developments such as immunotherapy, new methods to give chemotherapy such as use of catheter and the narrow tube connected to the brain so that the drug can act directly to the brain.
Pontine gliomas are the cancerous or malignant tumours that mainly originate from the part of the brain which is known as brain stem or pontine. They are usually developed from the cells which are known as astrocytes. Different symptoms for the tumour are abnormalities in eye movement, difficulty with balance, headache, nausea, weakness especially on one side of the face and many others. Main treatment option for the disease is surgery due to fast growth or overgrowth of the cancer cells in the pons part of the brain. Chemotherapy is not as much effective treatment option so doctors prescribe the drugs during or after the radiation therapy or surgery.
Increase in prevalence of pontine glioma can drive the pontine glioma treatment market growth. It is reported that in the United States, 300 children suffer each year and is one of the cause for the death. Mostly there are 80% of cases of DIPG. The incidence for the disease is 1 to 2 cases per 100,000. Increase in children population is also other reason for the pontine glioma treatment market growth. Other factors that can drive the pontine glioma treatment market growth are increase in clinical trials for the treatment of pontine glioma such as Johns Hopkins hospital has completed the clinical trial for the drug Melphalan hydrochloride which is used in the treatment of diffuse intrinsic pontine glioma (DIPG). Complications during the treatment and regrowth of the cancer cells after treatment are some of the factors that may hamper the pontine glioma treatment market growth. Ongoing clinical trials and increase in pipeline products are opportunities for the pontine glioma treatment market growth.
For instance,
- In December 2019, the U.S. FDA and European Medicines Agency granted the orphan drug to Adastra Pharmaceuticals. The drug was zotiraciclib (multikinase inhibitor) which is under clinical study and is used for the patient having glioblastoma.
The blood-brain barrier is one of the main challenging tasks for both researchers and the physicians that occur during the clinical trials and treatment. Chemotherapy failure is also one of the challenging factors that can hamper the pontine glioma treatment market growth.
This pontine glioma treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the pontine glioma treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Pontine Glioma Treatment Market Scope and Market Size
The pontine glioma treatment market is segmented on the basis of grade, classification, diagnosis, treatment, route of administration, end-user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of grade, the pontine glioma treatment market is segmented into grade I, grade II, grade III and grade IV.
- On the basis of classification, the pontine glioma treatment market is segmented into diffuse brain stem glioma, focal brain stem glioma and recurrent brain stem glioma.
- On the basis of diagnosis, the pontine glioma treatment market is segmented into computed tomography (CT) scan, biopsy and MRI.
- On the basis of treatment, the pontine glioma treatment market is segmented into surgery, radiotherapy and chemotherapy.
- On the basis of route of administration, the pontine glioma treatment market is segmented into oral and parenteral.
- On the basis of end-user, the pontine glioma treatment market is segmented to cancer research institutes, diagnostic laboratories, hospitals and others.
- On the basis of distribution channel, the pontine glioma treatment market is segmented into hospital pharmacy, retail pharmacy and others
Global Pontine Glioma Treatment Market Country Level Analysis
Global pontine glioma treatment market is analysed and market size information is provided by country, grade, classification, diagnosis, treatment, route of administration, end-user and distribution channel as referenced above.
The countries covered in the pontine glioma treatment market report are the U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, America accounts the largest market share because of increasing number of patients with brain stems tumour, increased healthcare expenditure and rapid awareness about the cancer among population. Asia-Pacific has the second largest market share especially in China due to expansion in the healthcare infrastructure and availability of untapped market opportunities. Middle East and Africa also shares a market share due to increase in medical tourism and patients having metastatic tumors.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The pontine glioma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to pontine glioma treatment market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the pontine glioma treatment market in the growth period.
Competitive Landscape and Global Pontine Glioma Treatment Market Share Analysis
The pontine glioma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global pontine glioma treatment market.
The major players covered in the global pontine glioma treatment market report are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-